PRODRUGS FOR NITROREDUCTASE BASED CANCER THERAPY- 2: Novel amide/Ntr combinations targeting PC3 cancer cells.
Amides
/ chemical synthesis
Antineoplastic Agents, Phytogenic
/ chemical synthesis
Cell Line, Tumor
Cell Proliferation
/ drug effects
Cell Survival
/ drug effects
Chromatography, High Pressure Liquid
Dose-Response Relationship, Drug
Drug Discovery
Drug Screening Assays, Antitumor
Humans
Molecular Dynamics Simulation
Molecular Structure
Nitroreductases
/ chemistry
PC-3 Cells
Prodrugs
/ chemical synthesis
Structure-Activity Relationship
Cytotoxicity
Enzymatic activity
Molecular docking
Nitro aromatic amides
Prodrug
Ssap-NtrB
Journal
European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510
Informations de publication
Date de publication:
01 Jun 2019
01 Jun 2019
Historique:
received:
28
12
2018
revised:
26
02
2019
accepted:
14
03
2019
pubmed:
1
4
2019
medline:
29
5
2019
entrez:
1
4
2019
Statut:
ppublish
Résumé
The use of nitroreductases (NTR) that catalyze the reduction of nitro compounds by using NAD(P)H in GDEPT (Gene-directed enzyme prodrug therapy) studies which minimize toxicity at healthy cells and increases concentration of drugs at cancer cells is remarkable. Discovery of new prodrug/NTR combinations is necessary to be an alternative to known prodrug candidates such as CB1954, SN23862, PR-104A. For this aim, nitro containing aromatic amides (A1-A23)
Identifiants
pubmed: 30928710
pii: S0223-5234(19)30253-3
doi: 10.1016/j.ejmech.2019.03.035
pii:
doi:
Substances chimiques
Amides
0
Antineoplastic Agents, Phytogenic
0
Prodrugs
0
Nitroreductases
EC 1.7.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
383-400Informations de copyright
Copyright © 2019 Elsevier Masson SAS. All rights reserved.